The in vitro anti-HIV efficacy of negatively charged human serum albumin is antagonized by heparin

AIDS Research and Human Retroviruses

Volumn 13, Issue 8, 1997, Pages 677-683

  Swart, P J ^a   Sun, C S ^b   Kuipers, M E ^a   Asuncion, C ^b   Josephs, S ^b   Smit, C ^a   Meijer, D K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HEPARIN; HUMAN SERUM ALBUMIN; SUCCINIC ANHYDRIDE; VIRUS ENVELOPE PROTEIN;

ANTICOAGULANT THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030995581     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.677     Document Type: Article

References (32)

1. Jouault T, Chapuis F, Bahraoui E, and Gluckman J-C: Infection of monocytic cells by HIV-1: Combined role of FcR and CD4. Res Virol 1991;142:183-188.
2. Montefiori DC, Zhou J, and Shaff DI: CD4-independent binding of HIV-1 to the B-lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exp Immunol 1992;90: 383-389.
3. Delibrias CC, Kazatchkine MD, and Fischer E: Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T-cells with opsonized HIV. Scand J Immunol 1993;38:183-189.
4. Lederman S, Gulick R, and Chess L: Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 1989;143:1149-1154.
5. Mbemba E, Chams V, Gluckman JC, Klatzmann D, and Gattegno L: Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate. Biochim Biophys Acta 1992;1138: 62-67.
6. Chams V, Idziorek T, Maddon PJ, and Klatzmann D: Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4. Antimicrob Agents Chemother 1992;36:267-272.
7. Batinic D and Robey FA: The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992;267:6664-6671.
8. Meshcheryakova D, Andreev S, Tarasova S, Sidorova M, Vafina M, Kornilaeva G, Karamov E, and Khaitov R: CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol Immunol 1993;30:993-1001.
9. Kamimoto Y, Tanabe D, Tashiro S, Hiraoka T, and Miyauchi Y: Changes in receptor-mediated endocytosis in liver sinusoidal cells after partial hepatectomy in the rat. Liver 1994;14:141-147.
10. Cardin AD, Taylor DL, Krstenansky JL, Tyms AS, and Jackson RL: A heparin which binds to the envelope glycoprotein gp120 inhibits human immunodeficiency virus replication. Trans Assoc Am Physicians 1989;102:101-109.
11. Jackson RL, Busch SJ, and Cardin AD: Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481-539.
12. Witvrouw M, Desmyter J, and De Clercq E: Antiviral portrait series. 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother 1994;5:345-359.
13. Baba M, Pauwels P, Balzarini J, Arnout J, Desmyter J, and De Clercq E: Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132-6136.
14. Offensperger WB, Offensperger S, Walter E, Blum HE, and Gerok W: Sulfated polyanions do not inhibit duck hepatitis-B virus infection. Antimicrob Agents Chemother 1991;35:2431-2433.
15. Meylan PRA, Kornbluth RS, Zbinden I, and Richman DD: Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob Agents Chemother 1994;38:2910-2916.
16. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, and Meijer DKF: Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 1991;39:818-823.
17. Swart PJ, Kuipers M, Smit C, Pauwels R, de Béthune M-P, De Clercq E, Huisman H, and Meijer DKF: Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus type 1 and 2 in vitro. AIDS Res Hum Retroviruses 1996;12:769-775.
18. Harmsen MC, Swart PJ, de Béthune M-P, Pauwels R, De Clercq E, The TH, and Meijer DKF: Antiviral effects of plasma and milk proteins: Lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J Infect Dis 1995;172:380-388.
19. Jansen RW, Schols D, Pauwels R, De Clercq E, and Meijer DKF: Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993;44:1003-1007.
20. Groenink M, Swart PJ, Broersen S, Kuipers ME, Meijer DKF and Schuitemaker H: Potent inhibition of replication of primary HIV-1 isolates by negatively charged human serum albumins. AIDS Res Hum Retroviruses 1997;13:179-185.
21. Swart PJ, Schutten M, Van Amerongen G, Smit C, Osterhaus ADME, and Meijer DKF: Pharmacokinetics of succinylated serum albumin in Wistar rats and cynomolgus monkeys: Implications for dosage regimens in the therapy of HIV infection. Drug Del 1996;3:165-171.
22. Swart PJ, Smit C, Pasma A, Beljaars E, Schuitemaker H, and Meijer DKF: Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J Drug Targeting 1996;4:109-116.
23. Kuipers ME, Huisman JG, Swart PJ, de Béthune M-P, Pauwels R, De Clercq E, Schuitemaker H, and Meijer DKF: Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120. J Acquir Immune Defic Syndr Hum Retroviruses 1996;11:419-429.
24. Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T: Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982;28: 219-228.
25. 131I labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114-123.
26. Dziarski R and Gupta D: Heparin, sulfated heparinoids, and lipoteichoic acids bind to the 70-kDa peptidoglycan/lipopolysaccharide receptor protein on lymphocytes. J Biol Chem 1994;269:2100-2110.
27. Javaherian K and Mcdanal C: Random copolymers containing specific ratios of negatively charged and aromatic amino acids bind V3 disulfide loop and neutralize diverse HIV type 1 isolates. AIDS Res Hum Retroviruses 1995;11:1163-1168.
28. Gordon LM. Waring AJ, Curtain CC, Kirkpatrick A, Leung C, Faull K, and Mobley PW: Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1995;11:677-686.
29. Pervin A, Gallo C, Jandik KA, Han XJ, and Linhardt RJ: Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology 1995;5:83-95.
30. Sugahara K, Tsuda H, Yoshida K, Yamada S, De Beer T, and Vliegenthart JF: Structure determination of the octa- and decasaccharide sequences isolated from the carbohydrate-protein linkage region of porcine intestinal heparin. J Biol Chem 1995;270:22914-22923.
31. Coombe DR, Harrop HA, Watton J, Mulloy B, Barrowcliffe TW, and Rider CC: Low anticoagulant heparin retains anti-HIV type 1 activity in vitro. AIDS Res Hum Retroviruses 1995;11:1393-1396.
32. Tyrrell DJ, Kilfeather S, and Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995;190:198-204.